Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigation of the Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression

NCT04821271 is registered in ClinicalTrials.gov with National Institute of Mental Health (NIMH) as lead sponsor.

NCT NCT04821271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04821271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigation of the Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
Lead sponsor
National Institute of Mental Health (NIMH)
Phase
Phase 2
Overall status
Terminated
Start date
June 10, 2021
Completion date
May 23, 2024
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder, treatment-resistant depression